CN104610384B - A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging - Google Patents
A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging Download PDFInfo
- Publication number
- CN104610384B CN104610384B CN201410637060.4A CN201410637060A CN104610384B CN 104610384 B CN104610384 B CN 104610384B CN 201410637060 A CN201410637060 A CN 201410637060A CN 104610384 B CN104610384 B CN 104610384B
- Authority
- CN
- China
- Prior art keywords
- afg
- aging
- arginine
- mouse
- maltose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of arginine disaccharide glycosides (AFG) artificial synthesis, suitable for industrialized production.I.e. arginine adds solid acid material, 20 DEG C of 100 DEG C of generation Maillard reactions of heating, generation arginine disaccharide glycosides (AFG) with maltose in thermostabilization solvent.Present invention is disclosed intraperitoneal injection D galactolipins (2.5g/kg) and D galactolipins (500mg/kg) cause mouse conspicuousness aging in 8 weeks is subcutaneously injected, can be respectively as the optimal dose for being injected intraperitoneally and being subcutaneously injected modeling.Mouse aging orally pours into AFG processing：AFG50mg/kg is remarkably improved mouse aging cerebral index, brain tissue TAC and skin hydroxyproline content etc., can imitate treatment mice age；AFG30mg/kg prevention administrations can significantly improve in mouse thymus index, skin superoxide dismutase levels etc. in hydroxyproline content and serum, can prevent mice age.AFG can improve senile organism TAC, and repair oxidativestress damage, have anti-aging effects, available for preparing antiaging agent.
Description
Technical field
The present invention relates to a kind of arginine disaccharide glycosides（AFG）Synthetic method and its application in terms of anti-aging.
Background technology
Arginine disaccharide glycosides (AFG) is in ginseng concocting process, and fresh ginseng occurs in baking stage maltose and arginine
Carbonyl aldehyde, which contracts and reacted to reset through Amadori, to be generated.Research finds that AFG not only has and promotes microcirculation[1], expansion blood vessel[2]With control
Treat diabetes[3]Deng pharmacological activity, it may additionally facilitate skin collagen synthesis and improve skin elasticity[4].AFG described in document is closed
It is into approach[5]：Under anhydrous glacial acetic acid environment, arginine and maltose mass ratio are 1:2,80 DEG C of reaction 0.5h ~ 1.0h, synthesis
Rate is about 27%, and thick synthetic has intense irritation tart flavour, therefore, it is necessary to find, a kind of synthetic ratio is high, nonirritant gas
The synthetic method of taste.
Along with the development of world's aging trend and the increase of job and life stress, disease aging and inferior health decline
Also become clear day by day always.Except genetic fragment lacks and is mutated[6-7]Outside, oxidativestress damage[8,9,10]It is cause aging most important
Reason.This experiment discussion AFG causes the inhibitory action of mouse subacute aging to D- galactolipins, according to medicines of the AFG in rat body
For dynamics[11]Understanding, main metabolic positions of the AFG in body is liver, also can act on brain by blood-brain barrier, because
This is according to mouse aging body changes of biochemical indexes, by detecting oxidation resistance in AFG administration groups mouse liver and brain tissue
Change judge its repair ability to mouse aging vivo oxidation stress damage.
Present invention
AFG synthetic methods：Arginine and maltose are so that without hydrothermally stable solvent, as reaction media, solid organic acid is catalysis
Arginine disaccharide glycosides is generated under the conditions of agent, heating and mixing（AFG）.
The present invention causes mouse subacute aging model modeling position and its optimal modeling dosage to optimize D- galactolipins,
Draw：Nape part hypodermic injection during the cause mouse subacute aging model modeling of D- galactolipins（SC）Better than intraperitoneal injection
(IP), and its optimal modeling dosage is respectively 0.5g/kg and 2.5g/kg.
AFG (50mg/kg) is disclosed by experiment in vivo, is remarkably improved the total antioxygen of cerebral index, brain tissue of mouse aging
Hydroxyproline content in change ability and skin, MDA and content of nitric oxide in brain tissue are significantly reduced, effectively treatment declines
Always；
Mice age symptom can be slowed down by disclosing AFG (30mg/kg) prevention administration by experiment in vivo, improved mouse thymus and referred to
Number, peroxide in superoxide dismutase levels, brain tissue TAC and liver in hydroxyproline content, serum in skin
Change hydrogen enzyme level, can be effectively pre- anti-aging.
The positive effect of the present invention is：
AFG synthetic method, synthetic ratio greatly improve in the present invention, up to 79%, while reduce being produced into for AFG
This, and thick synthetic has no irritating odor, acidic materials used in synthesis are common food additive, and glycerine is also food and change
Cosmetic additive, it is nontoxic nonirritant to human body, the safety in utilization of the thick synthetics of AFG is added, the raising of synthetic ratio adds
The paces that fast AFG moves towards the industrialization.
The present invention inquires into out the optimal modeling position of D- galactolipins cause mouse subacute aging by preliminary experiment and its most preferably made
Mould dosage, improve study anti-ageing medicine science disclose AFG have improve body TAC, notable repair machine
The oxidativestress damage of body, senile organism cerebral index and thymus index are improved, improve skin elasticity, general performance anti-aging is made
With.
The AFG of experimental example one synthesis and detection
1.AFG synthesis
1.1 accurate weighing 1.0g arginine, 2.0g maltose and 0.75g citric acids, are placed in the anhydrous glycerine of 20ml, mix
85 DEG C are heated under the conditions of even, is cooled down after reacting 2.5h ~ 3.0h, AFG concentration in thick synthesis is detected after dilution.
1.2 accurate weighing reaction substrates（1.0g arginine+2.0g maltose）4 parts, it is put in 20ml glycerine, according to
Secondary addition 1.5g, 1.0g, 0.75g and 0.5g citric acid, is heated to 85 DEG C, is cooled down after reacting 2.5h.Examined after thick synthetic dilution
Survey AFG concentration.
1.3 accurate weighing reaction substrates（1.0g arginine+2.0g maltose）Citric acid 0.5g is added, mixing is heated to 85
DEG C reaction 2.5h coolings, detect the change of AFG synthetic ratios after the dilution of thick synthetic.
1.4 setting blank control groups：85 DEG C of reaction 2.5h of 0.75g citric acids and 20ml glycerine.
1.5 other solid organic acids（Malic acid, benzoic acid and oxalic acid etc.）It is catalyzed AFG synthetic reactions, the same this patent of method
1.1。
The detection of the thick synthetics of 2.AFG
With column front derivation high performance liquid chromatography[5], with blank group（Glycerine 20ml+ citric acids 0.75g, 85 DEG C of reactions
2.5h）It is blank and control with AFG mark product, detects and calculate the production rate of AFG in thick synthetic.）
Chromatographic condition：Venusil-AA amino acid analysises dedicated columns (5 μm, the mm of 4. 6 mm × 250).Flowing
Phase A:Sodium acetate buffer solution-acetonitrile solution (pH=6. 5);Mobile phase B:Acetonitrile solution V (acetonitrile): V
(water)=4: 1.0 min, 0%B;4 min, 3% B;16 min, 10% B;17 min, 20% B;32min, 34% B;
34 min, 100% B;38 min, 0% B gradient elutions;The mL/min of flow velocity 1. 0;The nm of Detection wavelength 254;Column temperature
40℃ ;The μ L of sample size 20.
As a result
As shown in accompanying drawing 1,2, AFG mark product and the mixed marks of AFG+ARG compare the retention time that can be seen that AFG in mixed mark
Do not change, it may be determined that retention times of the AFG and ARG under this testing conditions is respectively 5.9min and 14.3min.Such as
Shown in accompanying drawing Fig. 3, blank control group, without appearance phenomenon, illustrates glycerine and citric acid in AFG and ARG retention times（Benzoic acid,
Malic acid and oxalic acid etc.）The material of interference AFG and ARG measure will not be produced under 85 DEG C of heating conditions.
As shown in Figure 4：Contain AFG in this patent method synthetic, and thick synthetic is diluted rear AFG and can directly examined
Survey.Illustrate that Maillard reaction generation arginine disaccharide glycosides occurs for arginine and maltose under citric acid, glycerine and heating condition
（AFG）.This synthetic method is feasible, efficient, and synthetic ratio is up to 72.45%.
As shown in accompanying drawing 5 ~ 8, and the thick synthetic of citric acid compare as can be seen that under equal experiment condition malic acid, benzene
Formic acid, oxalic acid and succinic acid can equally be catalyzed arginine maltose reaction generation arginine disaccharide glycosides（AFG）.It is possible thereby to sentence
Disconnected, acid solid organic acid, which is presented, in heating in thermostabilization solvent can be catalyzed Maillard reaction.
The D- galactolipins of example two cause the comparison at mouse subacute aging modeling position and the screening of corresponding dosage
1 experimental animal
SPF level ICR ♂ mouse 80,2 monthly ages, purchased from Bethune medical college of Jilin University Experimental Animal Center, credit number
For SCXK- (Ji) 2013-0003.Rearing conditions：23 ± 2 DEG C of temperature, humidity 55 ± 5%, feeds utilized is plain edition.
Experimental method
2.1 packets and administration（As shown in table 1）
The each group of table 1 is grouped and administrations
2.2 behaviouristics detect
The mouse state of mind, food ration, amount of drinking water, body weight and defecation situation are observed and recorded in administration process.
2.3 biochemical indicators detect
The dissection of the 8th weekend is administered, and 2 hours before dissection are administered, before last dose 12h fasting can't help water.Win eyeball
Take blood to put to death, 4200r/min under the conditions of 4 DEG C of blood centrifuged into 10min, draw that serum is standby, extracts brain, liver,spleen,kidney, thymus gland,
Weighed after the cleaning of ice physiological saline and calculate organ index.By brain tissue, serum and partial liver be stored under the conditions of -80 DEG C with
Indices to be detected.
2.4 statistical analysis
Processing data is carried out with SPSS17.0, is as a result represented with `x ± s, with one-way analysis of variance, P<0.05 thinks
It is statistically significant.
As a result
3.1 mice behaviors are observed
It is can be seen that from the state of mind, physiological site change, fur color and luster with excretion situation and ip groups compared with blank group
Mice age degree and D-Gal are high without significant change, sc into dose-effect relationship, sc group mouse D-Ga low dose group mouse morphological features
More subcutaneously joint group mouse shows more obvious aging state to dosage.Therefore draw a conclusion：The middle and high and subcutaneous high dose in abdominal cavity
The aging of group mouse is obvious.
The influence of 3.2 pairs of organ indexs.
Index and spleen index as shown in Figure 9：Ip-L+NaNO2 groups are extremely notable relative to blank group otherness（P＜ 0.01）Ip-H
Group and Sc-H groups are more significant with respect to blank（P＜ 0.01）, illustrate Ip-L+NaNO2 groups, Ip-H groups and Sc-H group Three doses
Make mouse splenomegaly.Spleen is one of peripheral immune organ, and splenomegaly generally to be regarded as the sign of some diseases[12], such as it is swollen
Knurl, hepatitis, acute and chronic infection etc..
As shown in attached 10, ip-M and nape part sc-H cause mouse thymus atrophy.Thymus gland is the important lymphoid organ of body,
Show more obviously with the age to increase and the phenomenon of change-degeneration than other organs（Atrophy）[13], i.e. thymus gland institute percentage of liveweight refers to
Number reduces, and therefore, atrophy of thymus gland is considered as the symptom of body aging.
TG, TC and the influence to brain tissue MDA, GSH in 3.4 pairs of serum (as shown in table 2,3)
Blood lipid level (`x ± s, n=8) in the serum of table 2.
Table 2 illustrates that D-Gal can cause TC and TG in mice serum significantly to raise by ip low dosages and ip high doses, D- half
Lactose sc low dosages and sc high doses can also cause TG in mice serum significantly to raise.Investigation and experiment display：Dyslipidemia is pair
An important factor for patients with aged metabolic syndrome kidney function damage[14], therefore three of the above dosage can be used as aging modeling dosage.
MDA contents and GSH are horizontal (`x ± s, n=8) in the brain tissue of table 3.
Table 3 is shown：Cause micro reduced glutathione in Mice brain tissues notable with ip methods injection D-gla middle dosages
Reduce（P＜ 0.01）；The injection of SC method D-gla high doses can cause the reductive glutathione content in group Mice Body to significantly reduce
（P＜ 0.05）, mda content significantly raises（P＜ 0.01）.Glutathione content is the important indicator for weighing mice age, its
Its brain aging degree of horizontal indirect reaction in brain tissue[15].MDA is lipid peroxidation product, is also referred to frequently as aging measure
Mark, its content increase and increased with aging degree[16]。
Comprehensive each dosage group influences to draw on serum, brain tissue and hepatic tissue：D-gla injects ip-M（2.5g/kg）And sc-
H（500mg/kg/d）56 days, obtained mouse aging, global index was notable compared with blank group otherness, and with usual aging December
Age above mouse index approaches[17,18,19], therefore can be using both dosage as ip and nape part sc optimal modeling agent
Amount.
The Antisenility Experiment of experimental example tri-arginine disaccharide glycosides
1 experimental animal and material
1.1 experimental animal（With experimental example two）
1.2 experiment material
Arginine disaccharide glycosides（AFG, laboratory self-control, purity 99.84%）, D- galactolipins（Shanghai pattern ocean biotechnology has
Limit company, analysis are pure）, Nimodipine（Bayer Schering Pharma, 06170438）.
Method
2.1. animal packet and processing
After adaptability is raised one week, mouse is divided into 7 groups at random.Respectively blank, model, Nimodipine, AFG treatments
Low, AFG treatments height, AFG preventions are low, AFG preventions are high.Suggested according to pharmacological methods：It is no more than per 10g mouse volume injecteds
0.2mL, then this experiment mice administered volume（mL）It is mouse weight（g）0.01 times.In addition to blank group, remaining each group is equal
Nape part is subcutaneously injected D- galactolipins 500mg/kg and causes mouse subacute aging model, positive drug and AFG administrations in 1 ~ 8 week
Mode is oral gavage.
The each group dosage of table 4. and administration time
2.2 Indexs measure
Mouse was dissected in the 8th week, was administered within 2 hours before dissection, before last dose 12h fasting can't help water.Eyeball takes blood collare
Vertebra dislocation is put to death, by 4200rmin under the conditions of 4 DEG C of blood-110min is centrifuged, it is horizontal to draw Virus monitory SOD.Extract brain, liver,
Thymus gland, weighed after the cleaning of ice physiological saline and calculate organ index.Detect in brain tissue in T-AOC, NO and MDA, liver CAT and
HYD in GSH and skin.
2.3 statistical analysis
Processing data is carried out with SPSS17.0, is as a result represented with `x ± s, one-way analysis of variance, P are used between group<0.05
To be statistically significant.
As a result
3.1 thymus indexs and cerebral index
The each group thymus gland of table 5 and cerebral index situation (`x ± s, n=8)
Thymus gland is the important lymphoid organ of body, and atrophy of thymus gland is the key character of body aging [13].Brain tissue is body
Nerve center, regulates and controls the Behavioral change of body, and the related Alzheimer's disease of aging is closely connected [20] with cerebral index.AFG
The cerebral index and thymus index of mouse aging can be significantly improved, illustrates that there is certain inhibitory action to aging, and low dosage
（30mg/kg）Act on thymus gland positive effect（P＜ 0.01）, and high dose（50mg/kg）It is notable to brain effect（P＜ 0.01）.
SOD levels and HYD contents in skin in serum
SOD levels and HYD contents (`x ± s, n=8) in skin in the serum of table 6.
| Group | Dosage (mg.kg-1) | SOD (u.ml-1) | HYD （μg.g-1） |
| Control | 0.9%NS | 128.64±9.07 | 5.55±0.59 |
| Model | 0.9%NS | 75.56±10.83## | 3.99±0.57## |
| Nimodipine | 16 | 73.26±5.37 | 4.41±0.72 |
| Prevent low dosage | 30 | 67.76±12.36 | 6.52±0.53** |
| Prevent high dose | 50 | 69.91±11.61 | 5.52±0.74** |
| Treat low dosage | 30 | 115.73±14.63** | 5.30±1.22** |
| Treat high dose | 50 | 134.29±12.17** | 6.42±0.59** |
SOD, CAT, GSH-Px and T-AOC etc. have collectively constituted body active oxygen system of defense, are body defending systems
Important component.TAC embodies the defence capability of body, and ceases manner of breathing with the generation of aging-related disease
Close, raising TAC can effectively treat or anti-aging[9,10].As shown in table 3, each dosage groups of AFG can effectively improve
SOD is horizontal in mouse aging serum（P＜ 0.01）With HYD in skin（P＜ 0.01）Content, effect is better than positive drug Buddhist nun not
It is flat.This explanation AFG can improve the oxidation resistance of mouse aging, and can improve skin elasticity, delay skin aging, demonstrate
AFG cosmetic result[4]。
T-AOC, MDA and NO change in 3.3 brain tissues
T-AOC, MDA and NO situation (`x ± s, n=8) in the brain tissue of table 7.
| Group | Dosage (mg.kg-1) | MDA(nmol.mgprot-1) | T-AOC(unit.ml-1) | NO((μmol.gprot-1)) |
| Control | 0.9%NS | 8.15±3.95 | 71.61±14.57 | 3.64±0.91 |
| Model | 0.9%NS | 13.98±6.76## | 15.62±7.65## | 5.16±1.75## |
| Nimodipine | 16 | 11.80±4.3 | 37.81±11.00** | 2.85±0.23** |
| Prevent low dosage | 30 | 8.22±2.5** | 31.45±14.128* | 3.68±0.75* |
| Prevent high dose | 50 | 8.13±2.19** | 49.88±14.50** | 3.43±0.76** |
| Treat low dosage | 30 | 8.11±2.59** | 65.52±4.32** | 3.04±0.78** |
| Treat high dose | 50 | 5.51±1.84** | 67.47±12.38** | 3.65±1.15* |
As shown in table 4, AFG significantly reduces lipid peroxidation product (MDA) and nitric oxide in mouse aging brain tissue
Content（P＜ 0.01）, significantly improve TAC in brain（P＜ 0.01）, and treatment group's high dose（50mg/kg）Effect is excellent
In low dosage（30mg/kg）；Prevention group low dosage（30mg/kg）Effect is better than high dose（50mg/kg）.In a word, AFG can be improved
Brain tissue TAC, the brain injury that aging is brought to body is reduced, reduce the morbidity risk rate of alzheimer.
CAT levels and GSH changes of contents in 3.4 livers
Influences of the AFG of table 8. to CAT and GSH in mouse aging liver
| Group | Dosage (mg.kg-1) | CAT(U.gHb) | GSH(μmol.gprot-1) |
| Control | 0.9%NS | 135.18±21.03 | 35.47±7.19 |
| Model | 0.9%NS | 83.06±8.57## | 19.26±3.24## |
| Nimodipine | 16 | 116.11±24.03 | 30.90±8.11* |
| Prevent low dosage | 30 | 123.90±12.49* | 19.51±1.96 |
| Prevent high dose | 50 | 115.95±33.09 | 23.00±4.33 |
| Treat low dosage | 30 | 124.16±15.69* | 22.82±4.33 |
| Treat high dose | 50 | 116.98±19.05 | 31.30±7.84** |
Glutathione content be weigh mice age important indicator, its liver aging journey of horizontal height indirect reaction
Degree[15].MDA is lipid peroxidation product, also increases with aging degree and increases frequently as Aging index, its content
Add[16].As shown in table 5, AFG low dosages（30mg/kg）Hydrogen peroxide enzyme level in liver can be significantly improved（P＜ 0.05）, it is high
Dosage（50mg/kg）Glutathione content can be significantly improved（P＜ 0.01）, AFG main metabolic position is liver, this explanation
AFG can improve liver TAC, have liver protection effect.
Comprehensive each index is drawn：AFG can improve mouse aging body TAC and body immunity, reduce oxygen
Change stress damage, protect liver and improve the functions such as skin elasticity.Low dosage AFG（30mg/kg）It is notable to the preventive effect of aging, and
High dose AFG（50mg/kg）It is stronger to the therapeutic effect of aging；AFG is low, high dose can improve mouse skin elasticity and reach
The effect of delay skin aging, overall testing index prove that AFG has anti-aging effects.
Brief description of the drawings
Fig. 1 AFG mark product.
Fig. 2 AFG mark product (black line) are compared with the mixed marks (grey lines) of AFG+ARG
Fig. 3 blank solvents (grey lines) are compared with the mixed marks (black line) of AFG+ARG
Fig. 4 AFG new methods synthesize crude product compared with the mixed marks of AFG+ARG.Black line：After the synthesis crude product dilution of AFG new methods
(citric acid), grey lines：The mixed marks of AFG+ARG
The thick synthetic of Fig. 5 lemon acid catalysis (black line) is compared with the thick synthetic of apple acid catalysis (grey lines).
The thick synthetic of Fig. 6 lemon acid catalysis is compared with the thick synthetic of apple acid catalysis.(the thick synthetic of lemon acid catalysis is (black
Line) compared with the thick synthetic (grey lines) of benzoic acid catalysis)
The thick synthetic of Fig. 7 lemon acid catalysis is compared with the thick synthetic of apple acid catalysis.(the thick synthetic of lemon acid catalysis is (black
Line) compared with the thick synthetic of Catalyzed by Oxalic Acid (grey lines))
The thick synthetic of Fig. 8 lemon acid catalysis is compared with the thick synthetic of apple acid catalysis.(the thick synthetic of lemon acid catalysis is (black
Line) compared with the thick synthetic of Catalyzed by Oxalic Acid (grey lines))
Influence of Fig. 9 D- galactolipins to each group mouse spleen index.
Influence of Figure 10 D- galactolipins to each group mouse thymus index.
Specific embodiment
Embodiment 1
Accurately weigh arginine：Maltose=1g:2g, glycerine 10ml and citric acid 0.1 being added, shaking table 160rpm is mixed,
20min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 1.17% are reacted under the conditions of 20 DEG C.
Embodiment 2
Accurately weigh arginine：Maltose=1g:2g, glycerine 10ml and citric acid 0.1 being added, shaking table 160rpm is mixed,
20min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 3.52% are reacted under the conditions of 40 DEG C.
Embodiment 3
Accurately weigh arginine：Maltose=1g:2g, glycerine 10ml and citric acid 0.1 being added, shaking table 160rpm is mixed,
20min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 8.28% are reacted under the conditions of 60 DEG C.
Embodiment 4
Accurately weigh arginine：Maltose=1g:2g, glycerine 10ml and citric acid 0.1 being added, shaking table 160rpm is mixed,
20min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 20.36% are reacted under the conditions of 80 DEG C.
Embodiment 5
Accurately weigh arginine：Maltose=1g:2g, glycerine 10ml and citric acid 0.1 being added, shaking table 160rpm is mixed,
20min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 25.36% are reacted under the conditions of 100 DEG C.
Embodiment 6
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
30min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 23.57% are reacted under the conditions of 80 DEG C.
Embodiment 7
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
60min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 40.19% are reacted under the conditions of 80 DEG C.
Embodiment 8
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
90min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 53.48% are reacted under the conditions of 80 DEG C.
Embodiment 9
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
120min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 62.17% are reacted under the conditions of 80 DEG C.
Embodiment 10
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
150min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 70.56% are reacted under the conditions of 80 DEG C.
Embodiment 11
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
180min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 70.00% are reacted under the conditions of 80 DEG C.
Embodiment 12
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.2 being added, shaking table 160rpm is mixed,
210min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 61.88% are reacted under the conditions of 80 DEG C.
Embodiment 13
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.5 being added, shaking table 160rpm is mixed,
120min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 51.26% are reacted under the conditions of 80 DEG C.
Embodiment 14
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.5 being added, shaking table 160rpm is mixed,
180min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 72.54% are reacted under the conditions of 80 DEG C.
Embodiment 15
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and citric acid 0.5 being added, shaking table 160rpm is mixed,
210min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 70.83% are reacted under the conditions of 80 DEG C.
Embodiment 16
Accurately weigh arginine：Maltose=1g:2g, adds glycerine 20ml and citric acid 1.0g, and shaking table 160rpm is mixed
It is even, 180min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 56.28% are reacted under the conditions of 80 DEG C.
Embodiment 17
Accurately weigh arginine：Maltose=1g:2g, adds glycerine 20ml and citric acid 1.5g, and shaking table 160rpm is mixed
It is even, 180min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 58.17% are reacted under the conditions of 80 DEG C.
Embodiment 18
Accurately weigh arginine：Maltose=1g:2g, adds glycerine 20ml and malic acid 1.0g, and shaking table 160rpm is mixed
It is even, 120min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 68.69% are reacted under the conditions of 80 DEG C.
Embodiment 19
Accurately weigh arginine：Maltose=1g:2g, adds glycerine 20ml and benzoic acid 1.0g, and shaking table 160rpm is mixed
It is even, 120min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 70.26% are reacted under the conditions of 80 DEG C.
Embodiment 19
Accurately weigh arginine：Maltose=1g:2g, glycerine 20ml and oxalic acid 1.0g being added, shaking table 160rpm is mixed,
120min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 60.75% are reacted under the conditions of 85 DEG C.
Embodiment 20
Accurately weigh arginine：Maltose=1g:2g, adds glycerine 20ml and succinic acid 1.0g, and shaking table 160rpm is mixed
It is even, 90min, column front derivation efficient liquid phase detection AFG contents, synthetic ratio 42.19% are reacted under the conditions of 85 DEG C.
Embodiment 21
Anti-aging pulvis
AFG powder in Example 1 after purification, vacuum, low pressure seal bottling, freeze dried powder is made.Make every bottle of AFG
Content is 0.35g.Other requirements meet《Pharmacopoeia of People's Republic of China》2010 editions relevant regulations about pulvis agent.
Embodiment 22
Anti-senility oral liquid
The AFG powder of Example 1 after purification, is configured to the 35mg/ml aqueous solution, is fitted into after sterilizing in vial, system
Into every 10ml oral liquid.Other requirements meet《Pharmacopoeia of People's Republic of China》2010 editions related rule about oral liquid
It is fixed.
Embodiment 23
Beauty and skin care water
The AFG powder purified in Example 1, add in surfactant matrix liquid, it is 200mg/ that AFG, which ultimately joins concentration,
100ml.Other requirements meet China cosmetic production requirement specification.
Bibliography
Effect [J] Jilin Agriculture University of the such as [1] Zheng Yinan, Zhang Jing, Okuda Takudox arginine derivatives to microcirculation
Journal, 1998,20（4）：45-47.
[2]Ishihara Takafumi, Okuda Takudo. Preparation of
arginylfructosylglucoses as vasodilators: Japan, 09316091[P].1997-12-09.
[3] a kind of preparation method of arginine glucosides of Zheng Yi men and its application in terms of diabetes are treated:China,
102178687[P].
2011-09-14.
[4]Han Li-Kun, Saito Masato,Nakagawa Yukiko,et al. Antioxidant
comprising arginyl-fructosyl-glucose,and use thereof: Japan, 2012140360[P]
.2012-07-26.
[5] in the quick American Ginsengs of Liu Li L-arginine and its derivative research [D] Jilin:Jilin Agriculture University, 2012.
[6]Kotoku Kurachi, Sumiko Kurachi, Kezhong Zhang, etal.Molecular
mechanisms of age-related regulation of genes[J].International Congress
Series, 2004,1262:562-565.
[7]Jeannette Loram, Andrea Bodnar.Age-related changes in gene
expression in tissues of the sea urchin Strongylocentrotus purpuratus[J]
.Mechanisms of Ageing and Development,2012,133:338-347.
[8]Qingwei Ruan, Fang Liu, Zhanjuan Gao, etal. The anti-inflamm-aging
and hepatoprotective effects of huperzine A in D-galactose-treated rats[J].
Mechanisms of Ageing and Development, 2013,134:89-97.
[9]Akiko Satoh, Takako Yokozawa, Eun Ju Cho, etal. Antioxidative
effects related to the potential anti-aging properties of the Chinese
prescription Kangen-karyu and Carthami Flos in senescence-accelerated mice
[J].Arch. Gerontol. Geriatr,2004,39:69-82.
[10]Weiqi Zhong, Ning Liu, Yanguang Xie, etal.Antioxidant and anti-
aging activities of mycelial polysaccharides from Lepista sordida[J].
International Journal of Biological Macromolecules, 2013,60:355-359.
[11] Wang Kun, Xu Xiaohua, Li Jiaqi, pharmacokinetics of the arginine disaccharide glycosides (AFG) in rat body is waited to grind
Study carefully [J] Jilin Auto Industries, 2014,36 (2):2-21813.
[12] the practical paediatrics magazine of the Dong Mei tumours hepatosplenomegaly related to blood disease [J] China, 2004,19 (6):
333-334.
[13] Gong opens refined thymus gland aging and immunosenescence [M] foreign medical science gerontology fascicles, 2009,30 (4):
145-149.
[14] influence [M] the internal medicine of the red dyslipidemias of Liu Jie, Song Yue to old metabolic syndrome patients' kidney function damage,
2009,4(4):525-527.
[15] Li Xiaoping, analogy training first, Yao Jianhua, wait Calciums to mouse aging glutathione and TAC
[J] China's pharmacology is influenceed with clinical, 2001,17 (1):21-22.
[16] Chen Yonglan, agriculture text field, face Xiao Fang, Ligusticum wallichiis are waited to mouse aging superoxide dismutase and MDA and hydroxyl
Influence [M] China and foreign countries' medical researches of free radical, 2012,10 (4):7-8.
[17] Zhu Yazhen, Zhu Hong light .D- galactolipins cause the foundation of aged animal model and its detection method [N] Fudan University to learn
Report, 2007,34 (4):617-619.
[18]Ji-Hun Park, Tae-Saeng. Choi. Polycystic ovary syndrome (PCOS)-
like phenotypes in the D-galactose induced aging mouse model[J].2012,427:701-
704.
[19] Chen Jun, Yang Guang, Liu Wen group mouse Antisenility Experiment and microorganism research on anti-senescence overview [J] China make
Make, 2011,6:13-16.
[20]Andras Bilkei-Gorzo. Genetic mouse models of brain ageing and
Alzheimer's disease[J]. Pharmacology & Therapeutics,2013.12.009。
Claims (2)
- A kind of 1. synthetic method of arginine disaccharide glycosides：Arginine, maltose and acidic materials are placed in glycerine, mix heating Generate arginine disaccharide glycosides；Specific method is as follows：Arginine and maltose are put into certain proportion in glycerine, add acid Property material 0.1-1.5g, 20 DEG C -100 DEG C heating 10min-200min, generate arginine disaccharide glycosides.
- 2. the synthetic method of arginine disaccharide glycosides as claimed in claim 1, it is characterised in that described acidic materials are lemon The mixed acid of one or both of acid, malic acid, oxalic acid and the above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410637060.4A CN104610384B (en) | 2014-11-11 | 2014-11-11 | A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410637060.4A CN104610384B (en) | 2014-11-11 | 2014-11-11 | A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104610384A CN104610384A (en) | 2015-05-13 |
| CN104610384B true CN104610384B (en) | 2018-02-27 |
Family
ID=53145061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410637060.4A Active CN104610384B (en) | 2014-11-11 | 2014-11-11 | A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104610384B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510241D0 (en) * | 2015-06-12 | 2015-07-29 | Takeda Pharmaceutical | Animal model |
| CN106467561B (en) * | 2015-08-19 | 2019-04-23 | 郑毅男 | A kind of quick separating, the method for purifying ginseng arginine glucoside |
| CN107011393A (en) * | 2016-03-24 | 2017-08-04 | 郑毅男 | A kind of arginine monoglycosides（AF）Novel synthesis and its purposes in terms of medicine |
| CN106912760A (en) * | 2016-09-30 | 2017-07-04 | 郑毅男 | A kind of preparation method of Jinseng health-care drink |
| CN109907102A (en) * | 2019-04-10 | 2019-06-21 | 珲春东扬实业有限公司 | A kind of processing technology of aquatic products |
| CN111592575B (en) * | 2020-06-10 | 2021-02-02 | 吉林农业大学 | Novel synthesis method of compound arginine diglycoside AFG |
| CN115160387B (en) * | 2022-07-20 | 2023-03-10 | 吉林农业大学 | Novel method for synthesizing compound arginine diglycoside AFG in red ginseng |
| CN116082421B (en) * | 2022-10-09 | 2023-07-07 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239030A (en) * | 2008-02-03 | 2008-08-13 | 郑毅男 | Red ginseng extract preparation and skin-protection product development thereof |
| CN102178687A (en) * | 2011-03-21 | 2011-09-14 | 郑毅男 | Preparation method of arginine glucoside and application in medicament for treating diabetes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09316091A (en) * | 1996-05-24 | 1997-12-09 | Bizen Kasei Kk | Production of arginylfructosylglucoses |
-
2014
- 2014-11-11 CN CN201410637060.4A patent/CN104610384B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239030A (en) * | 2008-02-03 | 2008-08-13 | 郑毅男 | Red ginseng extract preparation and skin-protection product development thereof |
| CN102178687A (en) * | 2011-03-21 | 2011-09-14 | 郑毅男 | Preparation method of arginine glucoside and application in medicament for treating diabetes |
Non-Patent Citations (4)
| Title |
|---|
| 人参加工品中精氨酸衍生物测定方法研究;曹国军，等;《中国药学杂志》;20031231;第38卷(第1期);第52-53页 * |
| 红参中新化合物精氨酸苷的生成机理及生成条件的研究;郑毅男，等;《中国药物化学杂志》;19970930;第7卷(第3期);第217-220页 * |
| 红参加工与精氨酸双糖苷（AFG）的形成;曹国军，等;《中药材》;20030228;第26卷(第2期);第97-98页 * |
| 红参加工过程中梅拉德初级反应产物的研究;杜芹芹，等;《化学学报》;20101231;第68卷(第13期);第1331-1336页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104610384A (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104610384B (en) | A kind of synthetic method of arginine disaccharide glycosides and its application in anti-aging | |
| Bailly et al. | Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? | |
| Li et al. | Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway | |
| Dong et al. | Studies on the antidiabetic activities of Cordyceps militaris extract in diet-streptozotocin-induced diabetic Sprague-Dawley rats | |
| US20220218798A9 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| Wang et al. | Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway | |
| Liu et al. | Tenuifolin, a secondary saponin from hydrolysates of polygalasaponins, counteracts the neurotoxicity induced by Aβ25–35 peptides in vitro and in vivo | |
| CN102264378A (en) | Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components | |
| CA3075988A1 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| Tang et al. | Protective effects of a traditional Chinese herbal formula Jiang-Xian HuGan on concanavalin A-induced mouse hepatitis via NF-κB and Nrf2 signaling pathways | |
| WO2016043517A1 (en) | Pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as active ingredient, mixture extract of moutan root bark, angelica dahurica root and bupleurum root or fraction thereof | |
| CN109045035B (en) | Application of 7- (2, 2-dimethyl-3-butenamido) -octahydro phenylquinoline acetate in preparation of medicine for treating liver diseases | |
| Liu et al. | Hepatoprotective effect of polysaccharide isolated from Sonneratia apetala fruits on acetaminophen-induced liver injury mice | |
| CN102731597B (en) | Abelmoschus manihot extract and novel application of chemical components thereof | |
| CN105503988B (en) | Natural antiepileptic activity compound and its purposes in pharmaceutical preparation | |
| KR102006659B1 (en) | A composition comprising ginsenoside Rh1 for preventing or treating sepsis | |
| CN107383150B (en) | A kind of compound and its preparation method and application with antihepatitis activity | |
| CN105777854A (en) | Pharmaceutical composition of etimicin sulfate and application of pharmaceutical composition in biomedicine | |
| CN105688197A (en) | Beriberi treatment drug containing lysozyme | |
| CN112807375B (en) | Application of Wangshi Baochi pill in preparation of medicine for preventing and/or treating alcoholic liver injury | |
| CN113521060B (en) | Application of NEEDOLIDE in resisting novel coronavirus | |
| KR101988882B1 (en) | A composition comprising ginsenoside Rk1 or Rg5 for preventing or treating sepsis | |
| CN103877071A (en) | Medicinal application of chicoric acid | |
| CN102631360A (en) | Application of oleanane glycoside to preparation of drugs for treating and/or preventing schistosomiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Sun Ronghua Inventor after: Zheng Shuangyang Inventor after: Chen Wei Inventor after: Ding Chuanbo Inventor after: Liu Wencong Inventor after: Zheng Yinan Inventor after: Zhao Ting Inventor after: Shao Ying Inventor after: Li Huiping Inventor after: Li Wei Inventor before: Sun Ronghua Inventor before: Zheng Yinan Inventor before: Shao Ying Inventor before: Li Wei Inventor before: Ding Chuanbo Inventor before: Li Huiping Inventor before: Song Mingming Inventor before: Wang Jiaqi |
|
| CB03 | Change of inventor or designer information |